Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Micronesia.
Press releases published on August 29, 2025

Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Research Methodology Followed Global and Regional Market Overview Global …

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive …

OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale NANTES, France - 29 août 2025, 8h00 CET – OSE Immunotherapeutics SA (ISIN: …

Santhera schliesst Vereinbarung mit Ikris Pharma Network über den Vertrieb von AGAMREE® (Vamorolon) in Indien
Pratteln, Schweiz, 29. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Ikris Pharma Network (Ikris) über den Vertrieb von AGAMREE® (Vamorolon) in Indien zur Behandlung von Duchenne- …

Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne …

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. …